Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer
2
조회
0
다운로드
2
인용
0
참고문헌
초록
Phospholipase D (PLD) is a potential therapeutic target against cancer. However, the contribution of PLD inhibition to the antitumor response remains unknown. We developed a potent and selective PLD1 inhibitor based on computer-aided drug design. The inhibitor enhanced apoptosis in colorectal cancer (CRC) cells but not in normal colonic cells, and in vitro cardiotoxicity was not observed. The inhibitor downregulated the Wnt/β-catenin signaling pathway and reduced the migration, invasion, and self-renewal capacity of CRC cells. In cancer, therapeutic engagement of immunogenic cell death (ICD) leads to more effective responses by eliciting the antitumor immunity of T cells. The CRC cells treated with the inhibitor showed hallmarks of ICD, including downregulation of “do not eat-me” signals (CD24, CD47, programmed cell death ligand 1 [PD-L1]), upregulation of “eat-me” signal (calreticulin), release of high-mobility group Box 1, and ATP. PLD1 inhibition subsequently enhanced the phagocytosis of cancer cells by macrophages through the surface expression of costimulatory molecules; as a result, the cancer cells were more susceptible to cytotoxic T-cell-mediated killing. Moreover, PLD1 inhibition attenuated colitis-associated CRC and orthotopically injected tumors, probably by controlling multiple pathways, including Wnt signaling, phagocytosis checkpoints, and immune signaling. Furthermore, combination therapy with a PLD1 inhibitor and an anti-PD-L1 antibody further enhanced tumor regression via immune activation in the tumor environment. Collectively, in this study, PLD1 was identified as a critical regulator of the tumor microenvironment in colorectal cancer, suggesting the potential of PLD1 inhibitors for cancer immunotherapy based on ICD and immune activation. PLD1 inhibitors may act as promising immune modulators in antitumor treatment via ICD.
Abstract
Phospholipase D (PLD) is a potential therapeutic target against cancer. However, the contribution of PLD inhibition to the antitumor response remains unknown. We developed a potent and selective PLD1 inhibitor based on computer-aided drug design. The inhibitor enhanced apoptosis in colorectal cancer (CRC) cells but not in normal colonic cells, and in vitro cardiotoxicity was not observed. The inhibitor downregulated the Wnt/β-catenin signaling pathway and reduced the migration, invasion, and self-renewal capacity of CRC cells. In cancer, therapeutic engagement of immunogenic cell death (ICD) leads to more effective responses by eliciting the antitumor immunity of T cells. The CRC cells treated with the inhibitor showed hallmarks of ICD, including downregulation of “do not eat-me” signals (CD24, CD47, programmed cell death ligand 1 [PD-L1]), upregulation of “eat-me” signal (calreticulin), release of high-mobility group Box 1, and ATP. PLD1 inhibition subsequently enhanced the phagocytosis of cancer cells by macrophages through the surface expression of costimulatory molecules; as a result, the cancer cells were more susceptible to cytotoxic T-cell-mediated killing. Moreover, PLD1 inhibition attenuated colitis-associated CRC and orthotopically injected tumors, probably by controlling multiple pathways, including Wnt signaling, phagocytosis checkpoints, and immune signaling. Furthermore, combination therapy with a PLD1 inhibitor and an anti-PD-L1 antibody further enhanced tumor regression via immune activation in the tumor environment. Collectively, in this study, PLD1 was identified as a critical regulator of the tumor microenvironment in colorectal cancer, suggesting the potential of PLD1 inhibitors for cancer immunotherapy based on ICD and immune activation. PLD1 inhibitors may act as promising immune modulators in antitumor treatment via ICD.
참고문헌 (42)
- Nelson, R. K., "Physiological and pathophysiological roles for phospholipase D", J. Lipid Res, 56, pp.2229~2237 (2015)
- Scott, S. A., "Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness", Nat. Chem. Biol, 5, pp.108~117 (2009)
- Brown, H. A., "Targeting phospholipase D in cancer, infection and neurodegenerative disorders", Nat. Rev. Drug Discov, 16, pp.351~367 (2017)
- Chen, Q., "Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis", Sci. Signal, 5, pp.ra79~ (2012)
- Kang, D. W., "Phospholipase D1 drives a positive feedback loop to reinforce the Wnt", beta-catenin, Cancer Res, pp.2010, 15[DOI]
- Kang, D. W., "Phospholipase D meets Wnt signaling : a new target for cancer therapy", Cancer Res, 15, pp.293~297 (2011)
- Martin-Orozco, E., "WNT signaling in tumors : the way to evade drugs and immunity", Front. Immunol, 10, pp.2854~ (2019)
- Galluzzi, L., "Immunogenic cell death in cancer and infectious disease", Nat. Rev. Immunol, 17, pp.97~111 (2017)
- Feng, M., "Phagocytosis checkpoints as new targets for cancer immunotherapy", Nat. Rev. Cancer, 19, pp.568~586 (2019)
- Tian, L., "Macrophage-based combination therapies as a new strategy for cancer immunotherapy", Kidney Dis, 8, pp.26~43 (2022)
- Krysko, D. V., "Immunogenic cell death and DAMPs in cancer therapy", Nat. Rev. Cancer, 12, pp.860~875 (2012)
- Ali, W. H., "Deficiencies of the lipid-signaling enzymes phospholipase D1 and D2 alter cytoskeletal organization, macrophage phagocytosis, and cytokinestimulated neutrophil recruitment", PLoS ONE, 8, pp.e55325~ (2013)
- Zhu, M., "Phospholipase D in T cell receptor-mediated signaling and T cell activation", J. Immunol, 200, pp.2165~2173 (2018)
- Göbel, K., "Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis", Eur. J. Immunol, 44, pp.2295~2305 (2014)
- Mor, A., "Phospholipase D1 regulates lymphocyte adhesion via upregulation of Rap1 at the plasma membrane", Mol. Cell Biol, 29, pp.3297~3306 (2019)
- decan-1-one derivatives, "Bioorg. Med. Chem. Lett", 2018, 3670~3673
- Bowling, F. Z., "Crystal structure of human PLD1 provides insight into activation by PI(4, 5)P2 and RhoA", Nat. Chem. Biol, 16, pp.400~407 (2020)
- Metrick, C. M., "Human PLD structures enable drug design and characterization of isoenzyme selectivity", Nat. Chem. Biol, 16, pp.391~399 (2020)
- Ahn, B. -H., "Transmodulation between phospholipase D and c-Src enhances cell proliferation", Mol. Cell Biol, 23, pp.3103~3115 (2003)
- Kang, D. W., "Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling β-catenin signaling in cancer-initiating cells", J. Exp. Med, 27, pp.1219~1237 (2015)
- Kim, J. H., "Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction", Bioorg. Chem, 112, pp.104907~ (2021)
- Min, D. S., "Expression and regulation of phospholipase D during neuronal differentiation of PC12 cells", Neuropharmacology, 41, pp.384~391 (2001)
- Vandenberg, J. I., "hERG K(+) channels: structure, function, and clinical significance", Physiol. Rev, 92, pp.1393~1478 (2012)
- Clevers, H., "Wnt", β-catenin signaling and disease, 2012, pp.149, 1192~1205
- Kang, D. W., "Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by Wnt", β-catenin and PI3K, Clin. Cancer Res, pp.2017, 23[DOI]
- Tago, K., "Inhibition of Wnt signaling by ICAT, a novel beta-catenininteracting protein", Genes Dev, 14, pp.1741~1749 (2000)
- Majeti, R., "CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells", Cell, 138, pp.286~299 (2009)
- Barkal, A. A., "CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy", Nature, 572, pp.392~396 (2019)
- Gordon, S. R., "PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity", Nature, 545, pp.495~499 (2017)
- Kelly, S. M., "Putting the brakes on phagocytosis : "don’t-eat me"signaling in physiology and diseases", EMBO Rep, 22, pp.e52564~ (2021)
- Gardai, S. J., "Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte", Cell, 123, pp.321~334 (2005)
- Obeid, M., "Calreticulin exposure dictates the immunogenicity of cancer cell death", Nat. Med, 13, pp.54~61 (2007)
- Dumitriu, I. E., "Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products", J. Immunol, 174, pp.7506~7515 (2005)
- Elliott, M. R., "Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance", Nature, 461, pp.282~286 (2009)
- Neufert, C., "An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression", Nat. Protoc, 2, pp.1998~2004 (2007)
- Yao, Y., "Phospholipase D as a key modulator of cancer progression", Biol. Rev. Camb. Philos. Soc, 95, pp.911~935 (2020)
- Luke, J. J., "WNT", β-catenin pathway activation correlates with immune exclusion across human cancers, 2019, pp.25, 3074~3083
- Ngo, T. B., "Physiological function of phospholipase D2 in anti-tumor immunity : regulation of CD8+ T lymphocyte proliferation", Sci. Rep, 8, pp.6238~ (2018)
- Xiao, Q., "DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation", Nat. Med, 24, pp.262~270 (2018)
- Chen, D. S., "Elements of cancer immunity and the cancer-immune set point", Nature, 541, pp.321~330 (2017)
- Loos, M., "Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer", Cancer Lett, 268, pp.98~109 (2008)
- Mu, C. -Y., "High expression of PD-L1in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation", Med. Oncol, 28, pp.682~688 (2011)